Antisense Oligonucleotides MarketRegional Analysis:-
North America is expected to bethe dominant region in the global AntisenseOligonucleotides Market over the forecast period. This is owing toincreasing approvals of new antisense oligonucleotide drugs in the region. Forinstance, in 2018, U.S. FDA approved Nusinersen, which is marketed as Spinrazafrom Biogen Inc.—a multinational biotechnology company. Nusinersen is the firstdrug approved for the treatment of Spinal muscular Atrophy (SMA). Moreover,robust pipeline is expected to contribute significantly to North Americaantisense oligonucleotides market growth. For instance, in 2017, Bio PathHolding’s—an oncology focused biotechnology company— drug BP 1001 (liposomalGrb2 antisense oligonucleotide) was in phase 2 clinical trials. BP 1001(liposomal Grb2 antisense oligonucleotide) is used to treat chronic myelogenousleukemia.
Key players in Europe are focusingon strategic mergers and acquisitions in order to enhance their productofferings in antisense oligonucleotides. This is further expected to aid ingrowth of the Europe antisense oligonucleotides market size. For instance, in2014, Astra Zeneca Plc.,—a multinational pharmaceutical and biopharmaceuticalcompany—merged with Ionis Pharmaceuticals, a pharmaceutical company. AstraZeneca Plc. has strategically merged with Ionis Pharmaceuticals to developdelivery methods for antisense oligonucleotides, which would help in targetingthe desired tissue more effectively. The other objective of this merger was todevelop Ligand Conjugation Antisense (LICA) Technology. Furthermore, robustpipeline of key players is also expected to aid in growth of the market to acertain extent. For instance, in 2016, Ionis Pharmaceuticals, a pharmaceuticalcompany completed phase 2 clinical trial of its drug IONIS STAT 3Rx. IONIS STAT3Rx is used in treatment of advanced cancers and lymphoma.
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/1879
Antisense oligonucleotides areshort, single stranded RNA or DNA molecules. Antisense oligonucleotides do notmodulate the activity of already formed proteins, however they act beforeproteins are produced at the level of messenger RNA in the cell. Antisenseoligonucleotides is used in treatment of oncology, Central nervous systemtherapeutics, inflammation therapeutics, diabetes, asthma, hair loss, etc.Antisense oligonucleotides is also used in genomics. Some examples of antisensenucleotides are fomivirsen to treat cytomegalovirus retinitis, mipomersen totreat high cholesterol, etc.
Antisense Oligonucleotides MarketDrivers:-
One of the major factors drivinggrowth of the global antisense oligonucleotides market is increasing number oflaunches pertaining to novel Antisense Oligonucleotides products by key playersin the market. For instance, in 2015, Exiqon A/S acquired by Qiagen launchednew LNA Antisense Oligonucleotide GapmeRs. LNA Antisense OligonucleotideGapmeRs is used for inactivation of RNA in functional analysis. Antisense LNAis an alternative to existing siRNAs. LNA Antisense Oligonucleotide aredesigned using advanced bioinformatics algorithm, which is combined with LNA(locked nucleic acid).
Furthermore, mergers andacquisitions by key players, in order to enhance their product offerings isexpected to be a major driver for global antisense oligonucleotides marketgrowth. For instance, in February 2018, Takeda Pharmaceuticals Company Ltd.—apharmaceutical company—merged with Wave Life Sciences Ltd., which is involvedin nuclei acid therapeutics. Takeda Pharmaceuticals has merged with Wave LifeSciences Ltd. to develop antisense oligonucleotides for central nervous systemdisorder, which includes Lou Gehrig’s disease, Frontotemporal dementia (FTD),Spinocerebellar ataxia type 3 (SCA3), and huntington’s disease. Lou Gehrig’sdisease is also called as Amyotrophic lateral sclerosis (ALS). This acquisitionwill also help Takeda in gaining market share.
Browse ResearchReport: https://www.coherentmarketinsights.com/ongoing-insight/antisense-oligonucleotides-market-1879
Robust pipeline is also anotherfactor aiding in growth of the global market. For instance, in 2016 IonisPharmaceuticals completed phase 2 clinical trials of its ISIS CRP Rx. ISIS329993 is an antisense oligonucleotide, which targets CRP (C reactive protein)in patients with paroxysmal atrial fibrillation. In 2015, Achieve Life Sciencescompleted Phase 2 clinical trials of its OGX 427. OGX 427 is used to treatcastration resistant prostate cancer.
Antisense Oligonucleotides MarketKey Players:-
Key players in global antisenseoligonucleotides market include Ionis Pharmaceuticals Inc., SareptaTherapeutics Inc., Biogen Inc., Alnylam Pharmaceuticals Inc., AntisenseTherapeutics Ltd., Isarna Therapeutics GmbH, Arrowhead Pharmaceuticals Inc.,Atlantic pharmaceuticals Inc., Enzon Pharmaceuticals Inc., Bio-Path HoldingsInc., Glaxo smith Kline Plc., Gene Signal International SA., Geron Corporation,Gradlis Inc., ICO Therapeutics Inc., Aptose Biosciences Inc., Marina BiotechInc., miRagen Therapeutics Inc., Synlogic Inc., OncoGenex Pharmaceuticals Inc.,Pharmaxis Ltd., Rexahn Pharmaceuticals Inc., Regulus Therapeutics Inc., and RxiPharmaceuticals Inc.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/1879
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN: +050-5539-1737
